American Society of Hirudotherapy

Complex Regional Pain Syndrome (Type I, Investigational)

Highly investigational adjunct for CRPS Type I; one case report and no controlled study identified; multidisciplinary pain management and physiotherapy remain primary.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 17, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for complex regional pain syndrome (CRPS). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
What evidence exists?
Tier C (investigational). No controlled trial of leech therapy for CRPS was identified; the only clinical report found is a single case report of one patient (Kulbida 2019). Evidence-based multidisciplinary care is essential: structured physical and occupational therapy with desensitization and graded motor imagery (the cornerstone), early aggressive pain control, sympathetic block or stellate ganglion block, bisphosphonates with the strongest RCT support for early CRPS, ketamine infusion in select centers, spinal cord stimulation for refractory cases, and integrated mental health support. CRPS is centrally mediated and responds best to early multidisciplinary intervention.
Main risks
  • Bleeding from each bite site for 6 to 24 hours after detachment
  • Bruising over the affected limb for 5 to 10 days
  • MAJOR RISK: CRPS limbs are exquisitely allodynic and any skin trauma can trigger severe flare
  • Risk of CRPS spread to a new limb or area
  • Local skin or, rarely, Aeromonas hydrophila infection
  • Allergic reaction to leech saliva (uncommon)
  • Delay of evidence-based multidisciplinary rehabilitation and pharmacotherapy
  • Psychological harm from a procedure that may amplify rather than reduce pain
Who should not consider this
  • Patients in early CRPS who have not yet started multidisciplinary rehabilitation
  • Patients with severe allodynia where any touch precipitates severe pain
  • Patients with active CRPS spread to additional limbs
  • Patients who have not tried bisphosphonates, sympathetic block, or other evidence-based therapies
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients with active dermatitis or broken skin over the affected limb
  • Patients with severe psychological distress that needs mental health intervention first
What to ask your clinician
  • Am I receiving structured multidisciplinary care - physical therapy, occupational therapy, pain medicine, and mental health?
  • Have I tried bisphosphonates (alendronate, pamidronate) early in CRPS?
  • Have I had a sympathetic block or stellate ganglion block?
  • Am I a candidate for ketamine infusion, spinal cord stimulation, or other interventional approaches at a CRPS center?
  • Why is leech therapy being considered given CRPS-related allodynia and spread risk?
  • What is the practitioner's plan if I have a severe flare?
  • What is the Aeromonas-prevention protocol?
When to seek urgent care
  • Sudden severe spread of CRPS symptoms to a new limb or body region
  • Sudden severe flare with intolerable pain unresponsive to usual medications
  • Acute swelling, coolness, or color change of the affected limb (possible CRPS escalation or DVT)
  • Bleeding from a bite site lasting more than 24 hours
  • Fever, chills, or spreading redness at the bite site
  • Hives, facial or throat swelling, or breathing difficulty
  • Severe psychological distress, suicidal thoughts, or hopelessness

What this does NOT mean

  • This is not FDA-cleared for CRPS.
  • No controlled trials support efficacy (the only clinical report identified is a single uncontrolled case report); CRPS responds best to multidisciplinary rehabilitation, not single procedural therapies.
  • It does not replace bisphosphonates, sympathetic block, ketamine, or spinal cord stimulation - all with stronger evidence in CRPS.
  • Trauma to an allodynic limb may trigger severe flare or contribute to CRPS spread.
  • CRPS is centrally mediated - peripheral procedures alone are insufficient.

Clinical Profile

Category
Neurological
ICD-10
G90.511, G90.512, G90.513, G90.519
Safety tier
High

Evidence Summary

CRPS Type I (reflex sympathetic dystrophy) follows Budapest Criteria diagnosis. Evidence-based management per IASP includes early mobilization, graded motor imagery, mirror therapy, multimodal analgesia (gabapentinoids, low-dose ketamine, sympathetic blocks), and bisphosphonates in selected cases. A single published case report (Kulbida et al., 2019, J Integr Med, PMID 31253578) describes a middle-aged man with chronic CRPS of the right hand who, after medicinal-leech treatments, was reported to have relief of symptoms, especially pain-intensity ratings and skin-temperature asymmetry, and improved active and passive mobility of the limb. This is one uncontrolled case, and no other clinical report or trial of leech therapy for CRPS was identified in PubMed, Europe PMC or ClinicalTrials.gov. CRPS pathophysiology (central sensitization, neurogenic inflammation, immune dysregulation) is complex and unlikely to respond reliably to peripheral leech application, and allodynia at proposed treatment sites is a practical limitation.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active deep vein thrombosis (acute phase)
  • Critical limb ischemia (ABI <0.4)
  • Severe allodynia at any potential placement site
  • Skin atrophy or trophic changes
  • Active osteoporosis at affected limb (bisphosphonate competing)
  • Sympathetic block within 2 weeks
  • CRPS-II (peripheral nerve injury) — different pathophysiology
  • Active dystonia or severe motor symptoms

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.